

Q3 2024 – Conference Call Note

Dr. Christian Hartel (CEO), Dr. Tobias Ohler (CFO) October 28, 2024

Disclaimer

The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.



Front page: WACKER has developed a new silane precursor for the manufacture of highly integrated memory chips and microprocessors. The new specialty chemical ensures the reliable and trouble-free functioning of highly integrated microchips for cloud computing and AI applications.

WACKER Q3 2024 Highlights

Financials



Operations



Sustainability /



€1.4bn

Sales (-6% yoy) Driven by lower solar-grade polysilicon volumes

€152m

EBITDA (Q3/23: €152m)

€34m

Net Income (Q3/23 €34m) 10.6%

EBITDA Margin (Q3/23: 10.0%)

€772m

Net Debt (31.12.23: €84m)

Higher Plant Utilization

Drives Chemicals EBITDA higher yoy and gog

US Tariff Uncertainty

Temporarily weighs on demand for solar-grade polysilicon

Efficiency Measures

Strong focus on costs and driving specific operating costs lower

Successful CO₂ Capture Pilot Study

The pilot plant achieved CO₂ capture rates >95% at the Holla site

Carbon capture is an important lever to achieve our NetZero by 2045 target

CMD Recap: Our 2030 Targets Refining Our Strategy to Adapt to Changing Market Conditions





CMD Recap: Group 2030 Targets Drive Group EBITDA Margin to >20% by 2030







CHEMICALS



- Grow high-margin specialties & capitalize on regional opportunities
- ▶ EBITDA margin: > 20%
- ▶ ROCE: > 2x cost of capital

BIOSOLUTIONS



- Leverage technology and fill new capacities
- ▶ EBITDA margin: > 25%
- ROCE: >> 1x cost of capital

POLYSILICON



- Continue Semi expansion & capitalize on regional solar prices
- ► EBITDA Margin: > 30%
- ▶ ROCE: > 2x Cost of Capital

CMD Recap: Clear Focus on Cost & Efficiency Measures



Digitalization & automatization

- Automation of production processes
- Advanced process control and machine learning



Specific initiatives 2024 - 2026


- Focus on maintenance spend & processes
- Reduce technical & indirect expenditures



Regionalization as cost & efficiency driver

- Excellence hub, Czech Republic, centralize support services
- Silicones site, Czech Republic, efficient production setup

CMD Recap: CapEx With Focus On Highly Profitable Growth





- Investments according to market environment
- Diversified portfolio of downstream projects

CMD Recap: Capital Allocation Priorities Solid Financial Foundation Supports Growth & Shareholder Returns

1) Growth

CapEx

CapEx > Depreciation

M&A

Earnings-accretive / early-stage bolt-ons



2) Shareholder returns

Dividend policy unchanged

~ 50% of net income from continuing operations



- Financial flexibility
- Net financial debt / EBITDA target at ~1.0x




Profit & Loss Statement Group Q3/24 EBITDA at €152m, with Chemicals EBITDA +€29m Higher YoY

Profit & Loss (€m)

1,430	1,523
213	198
14.9%	13.0%
152	152
10.6%	10.0%
37	49
2.6%	3.2%
34	34
0.56	0.56
	213 14.9% 152 10.6% 37 2.6%


Q3 Comments

- Sales -6% yoyVolume/Mix -4.7%, Price -1.3%, FX -0.5%
- Group EBITDA at prior year level
 Performance defined by high silicone specialties sales and low solar-grade polysilicon volumes



Balance Sheet Composition Resilient Financials with €4.6bn in Equity and €1.0bn in Liquidity

Balance sheet (%)




Characteristics 9/30/24

- Cash & securities: High level of liquidity at €1.0bn
- Working capital:
 +€370m higher due mainly to the higher inventory in POLYSILICON and lower trade payables
- Pension provisions:-€70m lower at €765m on higher discount rates
- Shareholder equity: Unchanged at €4.6bn



SILICONES Q3/24 EBITDA at €109m, Strong Specialties Sales







Comments Q3

- Specialties maintain strong volumes gog
- Pricing overall stable
- EBITDA supported by higher volumes, good mix and better plant loading qoq
- Uneven order patterns remain


FY 2024 Outlook

- Sales on PY level, with a low-double-digit % EBITDA margin
- Sales in all regions at PY level
- Higher volumes in Specialties

POLYMERS Q3/24 EBITDA at €46m, Supplier Force-Majeure and Weak Demand in China/Europe







CapEx (€m)



Comments Q3

- Consumer with good growth yoy
- Construction higher in America and MEA, offset by China and Europe
- EBITDA lower qoq due to a temporary supplier force majeure on ethylene in Germany


FY 2024 Outlook

- Sales lower (high-single-digit %) than PY with an EBITDA margin of around 15%
- Lower ASP with higher volumes in dispersions and stable volumes in DPP¹, regional dynamics unchanged to PY
- Consumer with good growth, construction markets remain soft in 2024

1) DPP = Dispersible Polymer Powder



BIOSOLUTIONS Q3/24 EBITDA at €14m, Growth in BioPharma




Comments Q3

- BioPharma drives Sales and EBITDA growth yoy and qoq
- First full quarter with German Pandemic Preparedness reservation fee
- Focus on filling new capacities

FY 2024 Outlook

- Sales approx. 10% higher than PY with a significantly higher EBITDA
- Sales growth driven by BioPharma and BioIngredients
- Growth in sales and earnings in H2/24

POLYSILICON Q3/24 EBITDA at €29m, Semi Resilient, Solar Uncertainty Remains




Comments Q3

- Sales and EBITDA decline yoy and qoq due to lower solar-grade volumes sold
- No further sales at low China domestic prices
- Uncertainty in solar continues as AD/CVD case proceeds
- Semi volumes and prices resilient

FY 2024 Outlook Updated

- Sales at approximately €1.1bn
- EBITDA €150 200m (excluding IRA)
- Share of semi products increasing
- Adjusting solar production in Q4

Net Financial Position Financials with a Net Debt of €772m



Appendix Modeling Help: OTHERS / U.S. IRA

OTHERS

- ▶ To ensure a true and fair view on segment performance we credit the expected payments (CO₂ compensation) quarterly to the segments, debiting OTHERS
- ▶ CO₂ compensation for FY 2024 will be received and recognized as income in the OTHERS segment in Q4/24
- Model the FY 2024 OTHERS segment EBITDA with -€20m before the contribution from Siltronic AG

U.S. IRA

- ▶ Tax credits for 2023 and 2024 will be accounted for in the POLYSILICON segment in Q4/24
- ▶ Guidance: The effect is included in Group guidance for FY 2024, but not in the POLYSILICON guidance
- ▶ Reported FY POLYSILICON EBITDA will be the sum of our guidance and the IRA credit


Appendix Q3 2024 Results


In €m	Q3 2024	Q3 2023	% YoY
Sales	1,430	1,523	-6%
EBITDA reported	152	152	0%
EBITDA-Margin	10.6%	10.0%	
EBIT	37	49	-24%
EBIT-Margin	2.6%	3.2%	
Net income for the period	34	34	0%
EPS	0.56	0.56	0%
CapEx	149	155	-4%
Net Cashflow	-99	128	-
Net Debt	772	164	>100%


Appendix Q3 2024 Results – Breakdown by Business

			Sales				E	BITDA			EBITDA	A Margin	(%)
In €m / %	Q3/24	Q3/23	% YoY	Q2/24	% QoQ	Q3/24	Q3/23	% YoY	Q2/24	% QoQ	Q3/24	Q3/23	Q2/24
Chemicals	1,092	1,066	2%	1,108	-1%	155	126	23%	149	4%	14.2	11.8	13.4
SILICONES	727	673	8%	719	1%	109	51	111%	90	21%	15.0	7.6	12.6
POLYMERS	365	393	-7%	389	-6%	46	75	-38%	59	-21%	12.6	19.0	15.0
BIOSOLUTIONS	100	77	29%	98	2%	14	-3	-	1	-	13.7	-4.0	1.1
POLYSILICON	209	342	-39%	232	-10%	29	46	-36%	55	-47%	14.0	13.5	23.8
Others	34	40	-17%	34	-2%	-46	-18	151%	-45	2%	-	-	-
Consolidation	-4	-4	17%	-4	5%	0	1	-	0	-	-	-	-
WACKER Group	1,430	1,523	-6%	1,468	-3%	152	152	0%	160	-5%	10.6	10.0	10.9

Appendix Key Raw Materials, Power and Gas









Appendix

Guidance: FY EBITDA Expected in Upper Half of Range

In €m	FY 2023	Outlook 2024
Sales	6,402	€6,000 – 6,500m
EBITDA	824	€600 – 800m
EBITDA margin (%)	12.9	Substantially lower than last year
Net cash flow	166	Negative, substantially lower than last year
CapEx	710	Slightly lower than last year
Net Debt	84	Higher than last year
Net Income	327	Substantially lower than last year
Depreciation	419	Around €450m
ROCE (%)	6.9	Substantially lower than last year
Tax Rate (%)	15.4	Around 20%

WACKER: Issuer, Contact and Additional Information

Issuer and Contact

INVESTOR RELATIONS CONTACTS

Joerg Hoffmann, CFA

Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com

Scott McCollister

Tel. +49 89 6279 1560 | scott.mccollister@wacker.com

Wacker Chemie AG

Gisela-Stein-Straße 1, D-81671 Munich investor.relations@wacker.com

Additional Information



ISIN DE000WCH8881 WKN WCH888

Deutsche Börse WCH

Financial Calendar

12/03/25 FY 2024 Results

30/04/25 Q1 2025 Results

07/05/25 Annual Shareholders Meeting

31/07/25 Q2 2025 Results **30/10/25** Q3 2025 Results

Publications









CUSTOMER MAGAZINE **FACTBOOK**

ANNUAL REPORT & ESG DISCLOSURES

SQUARE APP